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• NFI transcription factors play important roles in normal development and are associated 
with cancer in multiple organ systems. 
• NFI transcription factors are implicated in tumours that arise from cells that normally 
express the concordant transcription factor during development. 
• The role of NFI transcription factors in regulating the balance between cell proliferation 
and differentiation during development may be disrupted in cancer. 
• NFI transcription factors are context-dependent in various cancer types and can play 




The nuclear factor I (NFI) transcription factors play important roles during normal 
development and have been associated with developmental abnormalities in humans. All 
four family members, NFIA, NFIB, NFIC and NFIX, have a homologous DNA binding 
domain and function by regulating cell proliferation and differentiation via the 
transcriptional control of their target genes. More recently, NFI genes have also been 
implicated in cancer based on genomic analyses and studies of animal models in a variety 
of tumours across multiple organ systems. However, the association between their 
functions in development and in cancer is not well described. In this review, we 
summarise the evidence suggesting a converging role for the NFI genes in development 
and cancer. Our review includes all cancer types in which the NFI genes are implicated, 
focusing predominantly on studies demonstrating their oncogenic or tumour-suppressive 
potential. We conclude by presenting the challenges impeding our understanding of NFI 
function in cancer biology, and demonstrate how a developmental perspective may 










Cancer is driven by a series of acquired features that facilitate the initiation and 
progression of tumorigenesis by deregulating cellular proliferation and differentiation [1]. 
These features are acquired as a consequence of changes in gene expression, 
compromising physiological pathways that are normally regulated to ensure the function 
and maintenance of mature cellular phenotypes and optimal organ system performance. 
Not surprisingly, many pathways that are mis-regulated in cancer also function during 
normal development to control the rapid growth and development of each organ system 
[2]. Normal biological processes important for development, such as cellular proliferation, 
differentiation, and migration, are often compromised in cancer. As such, transcription 
factors that normally regulate these processes in development are often disrupted during 
tumorigenesis, either by direct mutation, or indirectly through chromosomal translocation. 
The pathways regulated by these transcription factors can be associated either with 
paediatric tumours during development or with adult cancers which result from mutations 
that revert mature cells to a developmental phenotype that enables rapid proliferation. In 
the last decade, genomic analyses and studies in mouse models have implicated such 
transcription factors in a variety of tumours across multiple organ systems.  
The NFI, or CCAAT box-binding transcription factor (CTF), family of genes was first 
described for its role in stimulating the initiation of adenovirus DNA replication. It was 
later found to play important roles in transcriptional regulation, particularly during 
development [3]. The NFI family consists of four transcription factors in humans and 
most vertebrates: NFIA, NFIB, NFIC, and NFIX [4]. These share a highly conserved 
DNA-binding domain at their N-termini, and therefore bind to a common DNA sequence 
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[5, 6] (Fig. 1). The C-termini of the NFI protein family demonstrate greater divergence, 
which is further compounded by the existence of multiple splice sites [7-11] and post-
translational modifications [12-16]. Consequently, each NFI transcription factor encodes 
multiple splice variants, although the functions of many of these remain unknown. 
NFI transcription factors regulate cell proliferation and differentiation during the 
development of multiple organ systems, including the central nervous system (CNS) [17-
23], mammary gland [24], and lungs [18, 25] (Fig. 2). These transcription factors are also 
required to drive hematopoiesis [26-31], osteoblastosis [32-34] and melanocytosis [35, 36] 
(Fig. 2). However, NFI deregulation can lead to uncontrolled cell proliferation or a failure 
to differentiate, and could therefore potentially contribute to tumour growth. In this 
review, we describe the oncogenic and tumour-suppressive potential of the NFI 
transcription factors and discuss what is known about the function of these genes in 
various types of cancer, in the context of their function in these same organ systems 
during development (Fig. 2). 
 
2. Central Nervous System Tumours 
2.1 Glioma 
In astrocytomas, high expression levels of NFIA [37] and NFIB [38] correlate with better 
clinical outcome (Table 1). For example, a high level of NFIA mRNA in adult grade IV 
glioblastoma (GBM) and paediatric grade III-IV astrocytomas is associated with 
improved survival [37] (Table 1). Similarly, high NFIB expression correlates with better 
overall survival probability in GBM, grade II-IV astrocytomas, and gliomas in general 
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[38] (Table 1). Higher-grade tumours are associated with lower NFIA [37] and NFIB [38] 
mRNA expression levels (Table 1). The percentage of cells that express NFIA protein, as 
detected by immunohistochemistry, is also reduced in higher-grade astrocytomas [37] 
(Table 1). These findings suggest that NFIA and NFIB function as tumour suppressors. 
This is corroborated by the identification of insertions that affect the NFI transcription 
factors in multiple insertional mutagenesis mouse models designed to identify genes 
involved in glioma tumorigenesis [39-41] (Table 2a). Notably, insertions within Nfic and 
Nfix have also been identified in these mouse models [41] (Table 2a), suggesting that 
NFIC and NFIX may also function as tumour suppressors in glioma.  
Genomic aberrations affecting NFIB are observed in approximately 40% of human 
astrocytomas, mainly as loss of heterozygosity (LOH) due to large deletions of 
chromosome 9p, which harbours other tumour suppressors such as CDKN2A [42-46]. 
Furthermore, NFIB overexpression induces cell differentiation and inhibits growth in 
GBM tumours, an outcome which is mediated by STAT3 signalling [38]. This implies 
that NFIB functions as an essential driver of glial differentiation in glioma. Its disruption 
results in the failure of tumour cells to differentiate, inevitably contributing to sustained 
cell proliferation. This scenario reflects NFI function in the developing brain, where 
disruption of Nfia, Nfib, and Nfix results in reduced and delayed differentiation of glial 
cells, causing progenitor cells to remain in a proliferative state [17-23]. During prenatal 
development, NFIA and NFIB are expressed within neural progenitor cells that give rise 
to various glial and neuronal cell populations throughout the brain and spinal cord [47-
49]. The high expression of these genes persists in both progenitor and differentiated cells 
of the adult brain, although their function in this case remains unknown [50]. 
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Nevertheless, their reduced expression in high-grade gliomas suggests that disruption of 
NFI activity is important in gliomagenesis [37, 38] (Table 1).  
Besides its potential role as a tumour suppressor, NFIA is also likely to act as a glioma 
type determinant. The percentage of NFIA-expressing cells in oligodendroglioma 
samples is consistently lower than in astrocytoma [37] (Table 1). Within the mRNA 
expression data of mixed glioma samples, low NFIA expression is associated with 
oligodendrogliomas and the enrichment of oligodendrocytic genes [51] (Table 1). Loss of 
NFIA as part of chromosome 1p31 also correlates with oligodendroglioma [52-54]. 
Furthermore, NFIA overexpression in a mouse model of oligodendroglioma resulted in 
tumours that resemble astrocytoma, suggesting a direct role for NFIA in regulating 
glioma subtype specificity [55].  
The role of NFIA as a cell fate determinant appears to be conserved during CNS 
development. For instance, down-regulation of NFIA favours the oligodendroglial lineage 
in the developing spinal cord [55]. In addition, both NFIA and NFIB play an essential 
role in generating astrocytes from human fibroblasts in vitro [56]. Interestingly, NFIA 
expression appears to be required for the later stages of oligodendroglial differentiation 
during postnatal brain development [57]. In the adult neocortex, NFIA is more highly 
expressed in oligodendroglia than NFIB and NFIX, suggesting a role in maintaining 
oligodendroglial differentiation [50]. Therefore, while NFIA and NFIB have a tumour-
suppressor role in astrocytoma, loss of NFIA could potentially contribute to 
oligodendroglioma in two ways, first as a glioma type determinant, and secondly by 
enhancing oligodendroglioma growth. 
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2.2 Medulloblastoma 
Various mouse models have demonstrated that loss of NFI also contributes to tumour 
initiation and progression in medulloblastoma. The Nfi loci have been identified as 
common insertion sites in insertional mutagenesis mouse models of medulloblastomas of 
the Sonic Hedgehog (SHH) subgroup [58-60] (Table 2a). Since many of these insertions 
are shared between the primary tumour and metastases, it is likely that insertions within 
the Nfi loci represent early events that contribute to tumorigenesis or tumour progression 
[60]. This role has been corroborated in a mouse model of SHH medulloblastoma with 
heterozygous loss of Nfia [58] (Table 2a). In these mice, reduced Nfia expression results 
in higher tumour incidence and decreased tumour latency [58]. These findings suggest 
that NFIA acts as a tumour suppressor of SHH-medulloblastoma.  
The role of Nfi in the postmitotic differentiation of cerebellar granule neurons (CGNs), 
the cell type that gives rise to SHH-medulloblastomas [61], has been extensively studied 
[62-65]. During postnatal cerebellar neurogenesis, mature CGNs within the internal 
granule cell layer (IGL) strongly express the NFI transcription factors, including NFIA 
and NFIB [62, 66]. Nfia deletion in mice disrupts postmitotic CGN differentiation within 
the IGL [62, 64]. Thus, the defective differentiation of CGNs due to the loss of NFIA 
could contribute to the initiation of SHH-medulloblastoma [58] (Table 2a). Although the 
role of NFIB in postmitotic CGN differentiation has not been investigated as Nfib 
knockout mice die perinatally, defects in CGN development were reported at embryonic 
day 18 [18]. Given that NFIB expression is elevated in mature CGNs [62], it is likely that 
loss of NFIB also contributes to the initiation of SHH-medulloblastoma. It should be 
noted, however, that the role of NFI in medulloblastoma could be molecular context-
	 10	
dependent. No Nfi insertions were reported in another insertional mutagenesis mouse 
model with Tp53 deletion [60]. Overall, the role of the NFI transcription factors in 
medulloblastoma highly correlates with their role in development. These findings suggest 
that further study of the NFI genes and the pathways that they regulate during cerebellar 




3.1 Adenoid cystic carcinoma 
The NFI transcription factors, particularly NFIB, appear to play a prominent role in 
various carcinomas, including adenoid cystic carcinoma (AdCC), breast carcinoma, and 
lung carcinoma (Table 3). In AdCC, MYB-NFIB fusion, or a similar fusion event 
affecting the MYB homologue, MYBL1, is found in 50% of tumours [67-76] (Table 3). 
This frequent fusion event is regarded as a molecular hallmark of AdCC [70, 75, 77]. 
Interestingly, this event always involves MYB fusing to the 3’ end of the NFIB locus, 
suggesting that preservation of this region is critical for AdCC tumorigenesis [68, 69, 73]. 
Indeed, it was recently reported that this fusion event allows NFIB enhancers to drive 
MYB expression, thereby establishing a positive feedback loop that sustains expression of 
the oncogenic MYB protein [78].  
Although increased expression of MYB or MYBL1 is crucial to AdCC tumorigenesis, 
NFIB is likely to play an independent role as a tumour suppressor. All reported MYB-
NFIB translocations disrupt the NFIB coding sequence [68, 69, 73] and independent 
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fusion events between NFIB and other fusion partners have been reported [70, 79-81] 
(Table 3). Moreover, the detection of truncating mutations and homozygous deletion of 
NFIB have also been identified in AdCC [70, 75, 78, 82]. These findings warrant further 
investigation of NFIB function in AdCC, particularly in cases where MYB or MYBL1 
expression is unaffected.  
Although the role of NFIB in salivary gland development has not been well studied, Nfib 
knockout mice display defects in terminal tubule formation and tubule cell differentiation 
during submandibular gland development [83]. Given that AdCC arises from epithelial 
cells of the secretory glands, most commonly the salivary glands of the head and neck 
[84], understanding the role of NFIB in salivary gland development could contribute to 
our understanding of how its loss is involved in AdCC. We speculate that the disruption 
of NFIB caused by the MYB-NFIB translocation perturbs epithelial cell differentiation, 
maintaining the proliferative state of these cells and thereby promoting AdCC 
tumorigenesis. 
 
3.2 Lung carcinoma 
In contrast to its potential tumour suppressor role in AdCC, NFIB appears to promote 
tumorigenesis in small cell lung cancer (SCLC). High expression or amplification of 
NFIB has been reported in both human and mouse primary SCLC tumours and cell lines, 
suggesting that NFIB functions as an oncogene in this tumour type [85, 86] (Table 1). 
Indeed, overexpression of NFIB promotes tumour initiation and metastatic progression in 
mouse models of SCLC in vivo [87-89] (Table 2b and 2c). One underlying mechanism 
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involves NFIB binding to chromatin and increasing its accessibility at distal regulatory 
elements that regulate pro-metastatic protein expression [87]. NFIB expression is also 
associated with increased cell proliferation in SCLC cell lines in vitro [85], whereas its 
knockdown induces the opposite phenotypes: reduced proliferation, and increased 
apoptosis and senescence [85, 89].  
The role of NFIB as an oncogene in lung carcinoma appears restricted to SCLC. In 
squamous cell carcinoma, no correlation was observed between NFIB expression and 
clinical outcome [90], while NFIB down-regulation is associated with poor clinical 
outcome and increased aggressiveness in non-small cell lung carcinoma (NSCLC) (Table 
1). Contrary to its role as a pro-metastatic oncogene in SCLC, NFIB is down-regulated 
during epithelial-to-mesenchymal transition (EMT) in a NSCLC cell line in vitro [91]. 
Coincidentally, mesenchymal-to-epithelial transition (MET), a process that normally 
occurs during lung development, is disrupted in the lungs of Nfib-deficient mice [18]. 
Specifically, the differentiation of type I and II epithelial cells is defective and the lung 
mesenchyme is thickened due to the increased number of mesenchymal cells [18]. 
Defective MET resulted in defects in lung maturation, causing Nfib-deficient mice to die 
at birth [18, 25]. These findings suggest that NFIB is essential for driving mesenchymal-
to-epithelial differentiation during lung development, and that it may also be required for 
epithelial cell maintenance following development. Consequently, loss of NFIB may play 
a role in the EMT of differentiated epithelial cells and epithelial stem cells in NSCLC 
[92], contributing to the development of these tumours. As SCLC arises from lung 
neuroendocrine cells [93], further studies are required to determine whether NFIB is 
required for the development of these cells, and how this process is maladapted in SCLC.  
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3.3 Breast carcinoma 
Overexpression or amplification of NFIB is a common feature of oestrogen receptor 
(ER)-negative breast carcinoma [94-98] (Table 1). Microarray analyses have 
demonstrated that NFIB expression is a predictor of extensive residual disease following 
taxane-anthracycline chemotherapy in ER-negative breast cancer [99]. As such, NFIB 
expression may be associated with cancer aggressiveness in this tumour type, with NFIB 
knockdown in vitro being shown to reduce proliferation in ER-negative breast cancer 
cells [95], demonstrating its oncogenic potential. NFIC, on the other hand, may function 
as a tumour suppressor in breast carcinomas. Overexpression of the NFI-C2 isoform in an 
ER-negative breast cancer cell line inhibits cell proliferation and tumour growth [9]. A 
similar observation has been reported for NFIC in ER-positive breast cancer cells, in 
which NFIC knockdown resulted in increased proliferation and the expression of the 
CCND1 oncogene [100]. Thus, NFIB may function as an oncogene in ER-negative breast 
cancer, whereas NFIC functions as a tumour suppressor in both ER-positive and ER-
negative breast cancers.  
NFIB and NFIC play essential roles in various stages of mammary gland development 
[24]. These transcription factors are highly expressed in terminally differentiated 
mammary epithelial cells during mammary gland development [8, 101], and are involved 
in the transcriptional regulation of mammary-specific proteins [14, 101-111]. Deletion of 
Nfib from mammary stem cells and differentiating alveoli, however, appears to have little 
or no impact on cell differentiation in the mammary gland [112], indicating that NFIB 
may be redundant for epithelial cell differentiation. NFI-C2 expression in epithelial cells 
decreases at lactation and is restored at involution [113], suggesting that NFI-C2 could be 
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required for epithelial cell differentiation and/or apoptosis but does not play a role in 
maintaining the differentiated cell state. Moreover, NFI-C2 up-regulates TP53 expression 
in the mammary gland during pregnancy [113]. Therefore, NFI-C2 likely functions as a 
protector against tumorigenesis during epithelial cell proliferation in mammary gland 
development.  
 
3.4 Other carcinomas 
Mis-regulation of the NFI transcription factors, or genomic aberrations that affect their 
gene loci, have also been observed in other carcinomas such as esophageal squamous cell 
carcinoma, hepatocellular carcinoma, and renal cell carcinoma (Table 3, Table 4). Based 
on current evidence, NFI transcription factors have both oncogenic and tumour 
suppressor potential, depending on the carcinoma type and its tissue of origin (Table 4). 
However, how the NFI transcription factors function in the development of these tissue 




4. Hematopoietic Tumours 
In the case of non-solid tumours, the NFI transcription factors have been implicated in 
hematopoietic tumours that include myeoloproliferative neoplasms, leukemia, and 
lymphoma. Specifically, point mutations, focal deletions, and translocations of NFIA 
have been found in myeloproliferative neoplasms [114, 115] and acute erythroid 
leukemia [116] (Table 3). Loss of NFIB due to 9p LOH was also reported in 
approximately 30% of myeloproliferative neoplasms [117-119], and in T-cell lymphomas 
(Sézary syndrome) [120]. These findings suggest a possible role for NFI in hematopoietic 
tumour development, as corroborated for T-cell lymphomas in an insertional mutagenesis 
mouse model where insertions within Nfia, Nfib and Nfic occur [121] (Table 2a).  
During development, NFIA is an important regulator of hematopoiesis, particularly in 
lineage fate decisions. NFIA overexpression, coupled to induced differentiation, is 
associated with megakaryocyte-erythroid progenitor differentiation [26, 27], whereas its 
down-regulation is associated with granulocyte-monocyte progenitor differentiation [27-
29]. Low NFIA expression in cells committed to the granulocyte-monocyte lineage 
further drives these cells to undergo monocytic differentiation [30, 31]. As a regulator of 
hematopoietic lineage commitment, disruption of NFIA could lead to the de-regulation of 
hematopoiesis. One possible outcome of this is uncontrolled erythroblastosis [116], 
ultimately contributing to the development of acute erythroid leukemia or 
myeloproliferative neoplasms [114, 115]. 
NFIB and NFIC are also required to drive megakaryocyte differentiation from 
megakaryocyte-erythroid progenitors. NFIB expression is up-regulated during induced 
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differentiation of megakaryocyte-erythroid progenitors [29], and megakaryocytes 
demonstrate increased expression of NFIB and NFIC [122, 123]. Loss of NFIB or NFIC 
in megakaryocyte progenitors is sufficient to prevent their differentiation, whereas their 
overexpression increases cell maturation [124]. Therefore, the excessive erythroblastosis 
in polycythemia vera could be attributed to defective megakaryocyte differentiation as a 
consequence of loss of NFIB [117-119].  
On the other hand, NFIX expression promotes myeloid lineage progression and 
suppresses lymphoid development in hematopoietic progenitors [125]. Loss of Nfix also 
causes apoptosis in murine hematopoietic stem cells [126]. However, its importance in 
hematopoietic tumours is yet to be investigated. Taken together, the NFI transcription 
factors are essential in regulating lineage progression, differentiation, and the survival of 
hematopoietic cells. The dysregulation of these proteins may contribute to hematopoietic 
tumour growth.  
 
5. Other Tumours 
NFI transcription factors have also been implicated in other tumour types such as 
melanoma, osteosarcoma, neurofibroma, and benign tumours, although their role in these 
tumours is less clear. In human melanomas, genomic aberrations within the NFI genes, 
including single nucleotide polymorphism and translocations, have been observed [127-
129] (Table 1, Table 3). Insertions within Nfia were also observed in tumours derived 
from an insertional mutagenesis melanoma mouse model [130] (Table 2a), suggesting 
that NFIA could act as a tumour suppressor in melanoma. NFIB expression, on the other 
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hand, correlates with more aggressive melanomas and promotes melanoma cell migration 
and invasiveness [35], suggesting that NFIB acts as an oncogene in this case. However, 
this role is contradicted by the inability of NFIB-overexpressing cells to form tumours 
when xenografted into immune-compromised mice [35]. Functional studies using uveal 
melanoma cells that originate from the same cell population that gives rise to cutaneous 
melanoma [131] have demonstrated that overexpression of NFIB and NFIC promotes cell 
migration and metastasis through suppression of an integrin subunit [132]. Inducing 
human melanoblast differentiation during development results in the down-regulation of 
NFIB expression [35], and its deletion in mice enhances melanocyte stem cell self 
renewal [36]. These findings demonstrate that NFIB expression is important in 
maintaining the quiescent state of melanocyte stem cells. This may explain why 
overexpression of NFIB in a pre-cultured melanoma cell line is insufficient to form 
xenograft tumours in mice [35].  
In human osteosarcomas, a missense coding SNP in NFIB and decreased NFIB 
expression have been associated with increased metastasis [133] (Table 1). A direct role 
for loss of NFIB in metastatic disease is substantiated by increased cell migration in vitro 
when NFIB levels are decreased [133] and the identification of disrupting insertions in 
Nfib in metastases collected from an insertional mutagenesis osteosarcoma mouse model 
[134] (Table 2a). These findings suggest that disruption of NFIB contributes to the 
osteosarcoma metastasis. This function is similar to its role in osteoblast development. In 
human osteoblast and bone formation, NFIB and NFIC are highly expressed and 
transcriptionally regulate cell proliferation, differentiation and survival through insulin-
like growth factor binding proteins [32]. In addition, the disruption of NFIC causes 
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defects in bone formation due to the failure of osteoblast differentiation and epithelial cell 
migration [33, 34]. Reduced expression of NFIC is also observed in dedifferentiated 
osteosarcoma cells [135]. These findings suggest that disruption of the NFI transcription 
factors perturbs cell differentiation and migration, possibly leading to tumorigenesis and 
metastasis.  
The NFI transcription factors have also been implicated in benign tumours, although the 
reasons for this remains unclear. For example, disruption of NFI promotes the 
progression of benign neurofibromatosis to malignant peripheral nerve sheath tumours as 
shown in insertional mutagenesis mouse models where insertions within Nfia or Nfib 
were identified [136] (Table 2a). In other benign tumours, only translocations involving 
NFIB have been reported, such as the HMGA2-NFIB translocations that are commonly 
found in lipoma [137, 138], pleomorphic adenoma [139], and uterine leiomyoma [140, 
141] (Table 3). Interestingly, the MYB-NFIB fusion that is characteristic of AdCC is also 
found in dermal cylindroma (Table 3), suggesting that similar pathways may be 
maladapted in these disorders [142]. 
 
6. Discussion 
6.1 The context-dependent roles of NFI in cancer 
Advances in high-throughput sequencing technologies have resulted in the identification 
of aberrations affecting NFI expression or function in various cancer types. Hence, there 
is now a body of evidence to suggest that the NFI family of transcription factors have 
both oncogenic and tumour-suppressive potential, depending on the context. This holds 
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true across different tumour types, but also applies to the role of the different NFI family 
members within a single tumour type. For instance, NFIB may be oncogenic in ER-
negative breast cancers and SCLC, but likely functions as a tumour suppressor in AdCC 
and GBM. Similarly, although it has been reported that high expression of both NFIA and 
NFIB correlates with improved clinical outcome and lower grade astrocytomas [37, 38], 
other studies have suggested that NFIA and NFIB can function in opposing roles. In vivo 
overexpression of NFIA in glioma promotes cell proliferation and tumour growth [200, 
201], whereas overexpression of NFIB induces differentiation, thereby halting tumour 
growth [38]. Finally, a single NFI transcription factor can perform opposing roles within 
the same tumour type, depending on the molecular context. Overexpression of NFIB 
inhibits cell proliferation and tumour growth by activating phospho-STAT3 signalling in 
STAT3-expressing GBM, but not in GBM without STAT3 expression [38]. It is likely 
that these differences are due to the transcriptional and post-translational regulation of the 
NFI genes themselves, and their subsequent recruitment of different molecular/protein 
co-activators or co-repressors to regulate downstream transcription. These differences 
accentuate the need to understand tumour context and the molecular pathways involved 
before assigning a function to specific NFI transcription factors in different cancer types. 
More importantly, careful consideration is required when targeting signalling pathways 





6.2 Regulatory mechanisms governing NFI expression 
NFI genes have been shown to be regulated in a variety of cancers through changes in 
gene copy number, both amplification of the gene and LOH, which alter mRNA 
expression, but this can also be altered via methylation and microRNA’s. Amplification 
of the NFIB locus and corresponding high NFIB expression have been reported in SCLC 
[85, 86], ER-negative breast carcinoma [94-98], and esophageal squamous cell carcinoma 
[196], suggesting that NFIB functions as an oncogene in these tumour types. In contrast, 
LOH or deletions causing low NFIB expression is common in astrocytomas [42-46], 
myeloproliferative neoplasms [117-119], T-cell lymphomas [120], and hepatocellular 
carcinoma [166, 197]. Similarly, LOH and  low NFIA expression was found in 
oligodendroglioma [52-54], myeloproliferative neoplasms [114, 115], and hepatocellular 
carcinoma [166, 197]. These studies suggest potential roles for NFIA and NFIB as tumour 
suppressors, which are also corroborated in insertional mutagenesis mouse models (Table 
2a), as well as in vitro and in vivo studies [37, 38].  
Promoter methylation of the different NFI promoters has not been well studied in the 
context of cancer. In a recent study of NSCLC samples with low NFIB expression, NFIB 
promoter hypermethylation was not observed, and only 6% of samples demonstrated 
NFIB copy number loss [90]. In these samples, NFIB was down-regulated as a result of 
tumour specific expression of miR-212 and miR-92b [90]. These findings suggest that 
microRNA dysregulation may be a common pathway resulting in NFI down-regulation in 
cancer. 
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The NFI loci are targeted by a number of miRNAs that are dysregulated in cancer, such 
as miR-21, miR-223, miR-124, miR-129, and miR-191 [28, 90, 153, 202-205]. For 
instance, expression of miR-124 and miR-129 in astrocytoma is inversely correlated with 
expression of their target NFIB and increased tumour grade [153, 205, 206]. Although in 
vitro experiments have demonstrated microRNA regulation of NFI in tumour cells in 
these cases [28, 90, 153, 202-204], the importance of NFI as a target in vivo remains to be 
determined. 
 
6.3 Structural variations alter function of NFI proteins 
The expression of naturally occurring NFI isoforms due to alternative mRNA splicing, 
particularly at the C-terminus transactivation domain (Fig. 1), might be a key determinant 
of the function of NFI proteins in development and cancer. Most differences between 
isoforms occur in the C-terminal transactivation and repression domain, and are likely to 
alter protein function. For example, the NFI-X1 isoform (Fig. 1, NFIX variant iv), in 
which exon 9 is skipped, is not able to induce glial fibrillary acidic protein (GFAP) 
expression [207]. On the other hand, the full length NFI-X3 isoform (Fig. 1, NFIX 
variant ii) can induce the expression of GFAP, resulting in astrocytic differentiation from 
neural progenitors [207]. This isoform also promotes the migration of glioma cells in 
vitro [11]. Some isoforms completely lack the DNA binding domain or transactivation 
domain and arelikely to result in the loss-of-function of these proteins. For example, the 
NFI-B3 isoform (Fig. 1, NFIB variant vii) lacks a transactivation domain and consists 
only of a truncated DNA binding domain. This isoform is able to bind to its motif in 
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DNA but does not activate gene transcription [7], suggesting that it may act as a 
dominant negative isoform and antagonise normal NFI function. Given that little is 
known about the precise function or expression of the different NFI isoforms, expression 
of specific NFI isoforms may explain the contradictory roles observed in some cancer 
types, such as thatof NFIB in SCLC and NSCLC. More in-depth analyses of available 
mRNA-sequencing data or proteomic analyses will be required to understand the function 
of NFI genes in different tumour contexts.  
 
6.4 Potential role of post-translational modifications on NFI protein function 
A further layer of complexity that requires consideration is how post-translational 
modifications of the NFI transactivation domain may affect their function (Fig. 1). For 
instance, phosphorylation of NFI is required to induce the expression of glial 
differentiation markers in glioma cells [15, 16], whereas glycosylation of NFI is 
mandatory in activating the transcription of whey acidic protein [8], and recruiting co-
activators, repressors or other nuclear regulatory targets [14] during mammary gland 
development. In contrast to its role in mammary gland development, glycosylation 
appears disruptive for NFI function in the differentiation of skin keratinocytes [13], 
suggesting that glycosylation of NFI could confer multiple functions. A major limitation 
of these studies is that they have not identified the exact amino acid residues that are 
modified [8, 12-16]. Other post-translational modifications of NFI, including 
SUMOylation [12] and acetylation [208], are also observed. However, similar to NFI 
phosphorylation, the physiological functions of these modifications have not been 
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determined. Hence, proteomic analyses such as mass spectrometry will be useful for 
identifying the presence of NFIpost-translational modifications in order to obtain a more 
accurate interpretation of NFI function in cancer. 
 
6.5 Potential impact of mutations on NFI function in cancer 
Mutations provide another scenario through which NFI function is altered in cancer. The 
most prevelant NFI mutation is the translocation of NFIB and MYB or MYBL in AdCC 
(Table 3). The presence of other translocation partners and nonsense mutations affecting 
NFIB in AdCC [70, 75, 78-82] suggest that NFIB may act as atumour suppressor in this 
tumour type. Although many other translocations involving NFI have been reported 
(Table 3), their functional consequence or relevance remains to be determined. 
Missense mutations in theNFI locihave been observed in up to 10% of melanoma and 
uterine carcinoma samples[209-211]. How these mutations affect NFI function remains 
to be determined, butno clear mutational hotspots or recurrent mutations are reported. It 
is likely that many of these mutations are passenger mutations due to the high mutation 
rate in some cancer types. 
Truncating mutations of NFI genes are uncommon, but have been reported for tumours in 
which a tumour suppressor role has been proposed, including AdCC [70], 
medulloblastoma [212], and GBM [184]. Such mutations may function as dominant 
negative mutations if they result in an antagonising function similar to NFI-B3. Thus, 
these mutations may provide additional evidence for the proposed role of NFI in these 
specific tumour types. 
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6.6 The convergent roles of NFI in development and cancer 
Despite these challenges, the role of the NFI transcription factors in regulating the 
balance between cellular proliferation and differentiation/quiesence during development 
appears conserved in the context of cancer. This is advantageous as it allows us to 
consider how the normal function of these genes might be disrupted in cancer, 
particularly in relation to tumour initiation and progression. For example, the NFI 
transcription factors and STAT3 bind to the GFAP promoter to drive astrocytic 
differentiation during development [213]. An appreciation of this relationship proved 
useful in our discovery that STAT3 is required for NFIB to inhibit proliferation in 
glioblastoma both in vitro and in vivo [38]. Similarly, the antagonistic relationship 
between SOX10 and NFIA in regulating glioma subtypes resembles their role in the 
lineage progression of glial cells during development [55]. 
In conclusion, the role of the NFI transcription factors in development is highly 
convergent with their role in cancer when their expression is disrupted. Also, there is  
appears to be a tendency for the NFI transcription factors to be implicated in tumours that 
arise from cells that normally express the concordant transcription factor during 
development. We posit that an in-depth understanding of the correlation between NFI 
function indevelopment and tumorigenesis will contribute greatly to understanding NFI 
function in cancer, and may ultimately be of prognostic and therapeutic value in 
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Figure 1 Schematic representations of the structural variability of the NFI transcription 
factors. Each exon is represented relative to its totalamino acid length. All NFI family 
members share a highly conserved DNA-binding and dimerization domain at their N-
termini (green box). The exon 1 region is variable due to alternative transcriptional start 
sites. The C-termini of the NFI proteins vary between family members and also between 
isoforms. Variants with similar structure, differing onlu in exon 1 are represented with a 
single variant. Boxes that have been lightly coloured represent exons with alternative 
reading frames within the same exonic region. Commonly detected phosphorylation and 
acetylation sites are portrayed in this figure [208]. Variants with corresponding 
ENSEMBL spliced transcript ID adopted from GENCODE v24 [214] are outlined in 




Figure 2 Organ systems in which the NFI genes are implicated, both during development 
and in cancer. During development, the NFI transcription factors are important for cell 
proliferation, differentiation, migration and lineage progression. These genes are also 
reported to function as oncogenes or tumour suppressor genes (TSG) in cancer, 




Table 1 Association of NFI expression with human tumour subtype, progression, cell 
characteristics, and response to treatment. 
Tumour Type NFI 
Member 
Association Findings Reference 
Bladder cancer NFIA Tumour 
progression 
Elevated NFIA mRNA expression is 
associated with T1 progressive bladder 
cancer, compared with T1 
nonprogressive tumours. 
Sharron 
Lin et al., 
2014 [143] 
NFIB Response to 
treatment 
High NFIB mRNA expression is 
associated with oxaliplatin resistance 
in bladder cancer. 
Kashiwagi 
et al., 2011 
[144] 
Breast  cancer NFIB Response to 
treatment 
High NFIB mRNA expression in 
primary breast cancer tumour samples 
is associated with a good pathologic 
response to neoadjuvant 
chemotherapy. 




NFIB Response to 
treatment 
High NFIB mRNA expression in ER-
negative breast cancer tumour 
samples is associated with a good 





Subtype High NFIB mRNA expression is 
associated with ER-negative subtype 







Colorectal cancer NFIB Response to 
treatment 
High NFIB mRNA expression is 
associated with oxaliplatin resistance 
in colorectal cancer. 
Kashiwagi 
et al., 2011 
[144] 
NFIX Response to 
treatment 
NFIX expression is associated with 
chemotherapy resistance in colorectal 
cancer patients. 







Subtype Low mRNA expression of NFI 
transcription factors is associated with 
C19MC amplified/LIN28+ embryonal 






NFIB Response to 
treatment 
High NFIB mRNA expression is 
associated with a good pathologic 
response to chemotherapy. 
Liu et al., 
2012 [148], 
Spentzos 
et al., 2005 
[149]  
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Elevated NFIB mRNA expression is 
associated with metastatic giant cell 
tumour of bone samples. 
Mosakhani 






Astrocytoma NFIA Cell 
characteristics 
NFIA is a transcriptional signature of a 
stemlike compartment in single-cell 
transcriptional profiles of primary 
glioblastoma tumours. 
Patel et al., 
2014 [152] 
Grade Low NFIA mRNA expression is 





Survival High NFIA mRNA expression is 
associated with better progression-free 







NFIB is a transcriptional signature of a 
stemlike compartment in single-cell 
transcriptional profiles of primary 
glioblastoma tumours. 
Patel et al., 
2014 [152] 
Grade Low NFIB mRNA expression is 





Survival High NFIB mRNA expression is 
associated with better overall survival 





Subtype Low NFIB mRNA expression is 







NFIB Subtype NFIB protein and mRNA expression is 
higher in anaplastic pilocytic 
astrocytoma (PA), compared with 
sporadic PA and NF1-PA. No strong 
NFIB expression is observed in dffuse 
glioma and non-neoplastic brain.  
Ho et al., 
2013 [153] 
Oligodendroglioma NFIA Glioma 
subtype 
The percentage of NFIA-expressing 
cells in oligodendrogliomas is 





Low NFIA mRNA expression is 
associated with oligodendrogliomas. 







Subtype High NFIB and NFIC mRNA 
expression is associated with 




Melanoma NFIA Tumour 
progression 
Low NFIA expression is associated 
with metastatic melanoma, compared 
with primary tumours. 
Kauffmann 




Lowered NFIB expression is 
associated with metastatic melanoma, 







NFIA Response to 
treatment 
Disruption of NFIA is associated with 




Osteosarcoma NFIB Tumour 
progression 
Lowered NFIB expression due to 
single nucleotide polymorphism is 
associated with increased 
osteosarcoma metastasis. 
Mirabello 
et al., 2015 
[133] 
Small cell lung 
cancer 
NFIB Subtype High expression or amplification of 
NFIB was observed in both human and 
mouse primary small cell lung cancer 







Uveal melanoma NFIB Tumour 
progression 
Lowered NFIB mRNA expression is 



















Table 3 Translocations of NFI in various tumours and cancer cell lines. 
Tumour Type NFI  Fusion  Tumour Location Cases Reference 
Adenocarcinoma NFIA DCLK1 Breast cancer 1/1019 Yoshihara 
et al., 2015 
[75] 
FAF1 Breast cancer 1/1019 Yoshihara 
et al., 2015 
[75] 
FGGY Breast cancer 1/1019 Yoshihara 
et al., 2015 
[75] 
HYI Breast cancer 1/1019 Yoshihara 
et al., 2015 
[75] 
LTV1 Breast cancer 1/1019 Yoshihara 
et al., 2015 
[75] 
ST6GALNAC3 Breast cancer 1/1019 Yoshihara 
et al., 2015 
[75] 
EHF Breast cancer* 1 Asmann et 
al., 2011 
[173], Ha et 
al., 2011 
[174], Klijn 








ATG4C Ovarian serous 
cystadenocarcinoma 
1/400 Yoshihara 
et al., 2015 
[75] 
INADL Ovarian serous 
cystadenocarcinoma 
1/400 Yoshihara 





et al., 2015 
[75] 
ZNF253 Rectum adenocarcinoma 1 Yoshihara 
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et al., 2015 
[75] 
NFIB HEATR5B Breast cancer 1/1019 Yoshihara 
et al., 2015 
[75] 
MYB# Breast cancer 1/1019 Yoshihara 
et al., 2015 
[75] 
MPDZ Breast cancer 1/1019 Yoshihara 
et al., 2015 
[75] 
STRN Breast cancer 1/1019 Yoshihara 
et al., 2015 
[75] 
ZDHHC21 Lung adenocarcinoma 1/487 Yoshihara 
et al., 2015 
[75] 
NFIC FZR1# Breast cancer 2/1019 Yoshihara 
et al., 2015 
[75] 
LRTOMT Breast cancer 1/1019 Yoshihara 
et al., 2015 
[75] 
WDR18 Breast cancer 1/1019 Yoshihara 
et al., 2015 
[75] 
CELF5# Ovarian cancer* 1 Yoshihara 
et al., 2015 
[75] 
NFIX DAND5 Breast cancer 2/1019 Yoshihara 
et al., 2015 
[75] 
Lung adenocarcinoma 1/487 Yoshihara 
et al., 2015 
[75] 
MAST1# Breast cancer 1/13 Robinson et 
al., 2011 
[176] 
MCU Breast cancer 1/1019 Yoshihara 
et al., 2015 
[75] 
TBCD Breast cancer 1/1019 Yoshihara 
et al., 2015 
[75] 
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BSG Breast cancer*  1 Edgren et 
al., 2011 
[178] 
GCDH Breast cancer* 1 Klijn et al., 
2015 [175] 
Lung adenocarcinoma 1/487 Yoshihara 





et al., 2015 
[75] 
 Adenoid cystic 
carcinoma 
NFIB MYB# Breast 4/4 Persson et 
al., 2009 
[73] 
Breast 10/12 Martelotto 
et al., 2015 
[179] 
Breast 2/4 Brill et al., 
2011 [68] 
Breast 6/31 D’Alfonso et 
al., 2014 
[180] 
Breast 12/13 Wetterskog 
et al., 
2012[181] 
Head and neck 7/7 Persson et 
al., 2009 
[73] 
Larynx 2/5 Brill et al., 
2011 [68] 
Salivary gland 21/30 Brill et al., 
2011 [68] 
Salivary gland 18/37 West et al., 
2011 [74] 
Salivary gland 59/91 Rettig et al., 
2015 [182] 
Salivary gland 32/60 Ho et al., 
2013 [70] 
Salivary gland 39/102 Mitani et al., 
2016 [80] 
Salivary gland 12/25 Rettig et al., 
2016 [79] 




Salivary gland 16/33 Fujii et al., 
2017 [76] 
Sinonasal cavity 5/7 Brill et al., 
2011 [68] 
Trachea/bronchus 7/12 Brill et al., 
2011 [68] 
Vulva 2/3 Brill et al., 
2011 [68] 
Mix samples 3/8 Costa et al., 
2014 [69] 
MYBL1 Salivary gland 12/102 Mitani et al., 
2016 [80] 
Salivary gland 2/25 Rettig et al., 
2016 [79] 
Salivary gland 3/20 Brayer et 
al., 2016 
[67] 
Salivary gland 2/33 Fujii et al., 
2017 [76] 
AIG1 Salivary gland 1/102 Mitani et al., 
2016 [80] 
MAN1A1 Salivary gland 1/60 Ho et al., 
2013 [70] 
MAP3K5 Salivary gland 2/25 Rettig et al., 
2016 [79] 
MYO6 Salivary gland 1/25 Rettig et al., 
2016 [79] 
NKAIN2 Salivary gland 1/102 Mitani et al., 
2016 [80] 
PTPRD Salivary gland 1/102 Mitani et al., 
2016 [80] 
RIMS1 Salivary gland 1/25 Rettig et al., 
2016 [79] 
RPS6KA2 Salivary gland 1/25 Rettig et al., 
2016 [79] 
XRCC4 Salivary gland 1/102 Mitani et al., 
2016 [80] 
 Other carcinomas NFIA SCP2 Non-small cell lung 
cancer* 
1 Klijn et al., 
2015 [175] 
NFIB FREM1 Lung squamous cell 
carcinoma 
1/220 Yoshihara 
et al., 2015 
[75] 
NFIC C16orf55 Adrenocortical carcinoma 1 Yoshihara 
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et al., 2015 
[75] 
FZR1# Cervical squamous cell 
carcinoma 
1 Yoshihara 
et al., 2015 
[75] 
LSM7 Cervical squamous cell 
carcinoma 
1 Yoshihara 




1 Klijn et al., 
2015 [175] 
ZNF653 Lung squamous cell 
carcinoma 
1/220 Yoshihara 
et al., 2015 
[75] 
NFIX DOCK6 Esophageal carcinoma 1 Yoshihara 
et al., 2015 
[75] 
MAST1# Lung carcinoma* 1 Klijn et al., 
2015 [175] 
RALGPS1 Oral cavity squamous 
cell carcinoma 
1 Yoshihara 
et al., 2015 
[75] 
Head and neck 
squamous cell carcinoma 
1/300 Yoshihara 
et al., 2015 
[75] 
GATAD2A Thyroid carcinoma 1/494 Yoshihara 
et al., 2015 
[75] 
 Other cancers NFIA CBFA2T3 Acute erythroid leukemia 1 Micci et al., 
2013 [116] 
NCOR1 Acute lymphoblastic 
leukemia 
1/255 Liu et al., 
2017 [183] 
RNLS Glioblastoma 1/101 Frattini et 
al., 2013 
[184] 
1/175 Shah et al., 
2013 [185] 
AKD1 Medulloblastoma 1/79 Robinson et 
al., 2012 
[186] 
TNNI3K Melanoma 1/25 Berger et 
al., 2012 
[127] 
RAF1 Pilocytic astrocytoma 1 Yde et al., 
2016 [187] 
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NFIB C12orf42 Multiple myeloma 1/38 Chapman 
et al., 2011 
[188] 
NFIC CELF5# Low-grade glioma 1/266 Yoshihara 
et al., 2015 
[75] 
BRAF Melanoma 1/531 Kim et al., 
2017 [129] 
NFIX MAST1# Melanoma 1/25 Berger et 
al., 2012 
[127] 




 Benign tumours NFIB HMGA2 Lipoma 1 Pierron et 
al., 2009 
[190] 
Lipoma 1/2 Nilsson et 
al., 2005 
[138] 
Lipoma 2/29 Dadone et 
al., 2015 
[191] 
Lipoma 2/5 Italiano et 
al., 2008 
[137] 
Lipoma 1 Lacaria et 
al., 2017 
[192] 
Pleomorphic adenoma 2/28 Asp et al., 
2006 [193] 
2/2 Geurts et 
al., 1998 
[139] 




Table 4 The putative roles of NFI in other carcinomas. 









Down-regulation of NFIB is common 
in both cell lines and tumour 
samples, and drives tumour 
progression. 
Zhou et al., 
2015 [194], 




NFIB Oncogene NFIB locus is amplified in primary 








Copy number loss of NFIA has been 









Copy number loss of NFIB has been 







Oncogene Knockdown of NFIB inhibits tumour 




Renal cell carcinoma NFIC Oncogene Up-regulation of NFIC is observed in 











Variants ENSEMBL Spliced Transcript ID 






NFIB i ENST00000380953.5 








NFIC i ENST00000589123.5, ENST00000443272.2 




NFIX i ENST00000588228.5 
ii ENST00000592199.5, ENST00000585575.5 
iii ENST00000358552.7, ENST00000360105.8 
iv ENST00000397661.6, ENST00000587760.5, ENST00000587260.1 
	
 
 
 
